Merus/$MRUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Primary listing
Employees
291
Headquarters
Website
Merus Metrics
BasicAdvanced
$7.2B
-
-$5.57
1.19
-
Price and volume
Market cap
$7.2B
Beta
1.19
52-week high
$95.06
52-week low
$33.19
Average daily volume
3.7M
Financial strength
Current ratio
8.389
Quick ratio
7.981
Long term debt to equity
1.04
Total debt to equity
1.307
Profitability
EBITDA (TTM)
-344.534
Gross margin (TTM)
-93.94%
Net profit margin (TTM)
-685.64%
Operating margin (TTM)
-617.08%
Effective tax rate (TTM)
-2.24%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-23.16%
Return on equity (TTM)
-48.54%
Valuation
Price to revenue (TTM)
116.828
Price to book
8.52
Price to tangible book (TTM)
8.54
Price to free cash flow (TTM)
-20.966
Free cash flow yield (TTM)
-4.77%
Free cash flow per share (TTM)
-4.526
Growth
Revenue change (TTM)
59.77%
Earnings per share change (TTM)
92.38%
3-year revenue growth (CAGR)
2.17%
10-year revenue growth (CAGR)
35.87%
3-year earnings per share growth (CAGR)
62.97%
10-year earnings per share growth (CAGR)
-1.85%
What the Analysts think about Merus
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Bulls say / Bears say
The U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in combination with pembrolizumab for first-line PD-L1+ r/m head and neck squamous cell carcinoma in February 2025, expediting its development path (Nasdaq turn9search0)
Merus completed a public offering in June 2025, raising $345 million gross and resulting in $892 million in cash, cash equivalents and marketable securities as of June 30, 2025, sufficient to fund operations into 2028 (Merus Q2 2025 Press Release turn8view0)
Interim data from the phase 2 trial of petosemtamab with pembrolizumab presented at ASCO 2025 demonstrated a 63% response rate among 43 evaluable patients, underscoring robust clinical efficacy in first-line HNSCC (Merus Q2 2025 Press Release turn8view0)
Research and development expenses surged by $44.8 million in Q2 2025 versus Q2 2024, reflecting escalating cash burn that could strain Merus’s cash runway absent product revenues (Merus Q2 2025 Press Release turn8view0)
Collaboration revenue growth was a modest $1.5 million in Q2 2025 year-over-year, underscoring Merus’s continued reliance on partnership deals rather than product sales for income (Merus Q2 2025 Press Release turn8view0)
Merus’s accumulated deficit ballooned to $1.223 billion as of June 30, 2025, highlighting prolonged unprofitability and raising concerns about potential future equity dilution (Merus Q2 2025 Press Release turn8view0)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Merus Financial Performance
Revenues and expenses
Merus Earnings Performance
Company profitability
Merus News
AllArticlesVideos
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Business Wire3 days ago
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Business Wire4 weeks ago
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Benzinga4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $7.2B as of October 26, 2025.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of October 26, 2025.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.